1130. Ensovibep antiviral activity in ambulatory patients with COVID-19 is independent of baseline anti-SARS-CoV-2 antibodies and exhibits minimal selective pressure – Results from the placebo-controlled EMPATHY trial

BACKGROUND: Ensovibep is a multi-specific DARPin (designed ankyrin repeat protein) antiviral in clinical development for treatment of COVID-19. In the Phase 2 EMPATHY study, ensovibep demonstrated greater viral load decline versus placebo. Here we report (1) the efficacy of ensovibep in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Abrishamian, Luis, Bonten, Marc, Chandra, Richa, Elango, Damodaran Solai, Fustier, Pierre, Gedif, Kinfemichael, Goncalves, Susana, Igbinadolor, Awawu, Kingsley, Jeff, Knutson, Charles G, Kukkaro, Petra, Kumarasamy, Nagalingeswaran, Legenne, Philippe, Mekebeb-Reuter, Martha, Ramanathan, Krishnan, Reshetnyak, Evgeniya, Robinson, Michael, Rosa, Jennifer, Soergel, Marianne, Stavropoulou, Vaia, Stojcheva, Nina, Stumpp, Michael T, Tietz, Andreas, Zhao, Xiaojun, Zhang, Zhaojie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752393/
http://dx.doi.org/10.1093/ofid/ofac492.969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752393/
http://dx.doi.org/10.1093/ofid/ofac492.969

Ejemplares similares